« Back to Farmacia Journal 3/2025

IMPACT OF EDARAVONE DEXBORNEOL TREATMENT ON NEUROLOGICAL FUNCTION, COGNITIVE FUNCTION, AND INFLAMMATORY-OXIDATIVE STRESS STATUS IN PATIENTS WITH ACUTE PROGRESSIVE CEREBRAL INFARCTION

ZIJIAN FAN *, XINWEI HE, LINKAO CHEN, MAN QU, LINGQUN MAO

Download Full Article PDF

Acute progressive cerebral infarction (APCI) is marked by worsening symptoms and neurological decline with high mortality. This study aimed to compare the clinical efficacy of edaravone (Eda) and edaravone dexborneol (Eda.B) in APCI treatment. Clinical data from 98 APCI patients were retrospectively analysed: 48 received Eda and 50 received Eda.B intravenously for 2 weeks. Hemorheological parameters, neurological and cognitive function (NIHSS, MoCA, BI), serum inflammatory and oxidative stress markers (IL-6, IL-17, IL-1β, MMP-9, MDA, SOD, GSH-Px), and cerebral perfusion (MRI-based) were evaluated. Compared to Eda, Eda.B significantly reduced blood viscosity indices and erythrocyte sedimentation rate, improved NIHSS, MoCA, and BI scores, and favourably modulated inflammatory-oxidative markers. Eda.B also enhanced cerebral blood volume and flow, while reducing mean transit time and time to peak. The clinical efficacy rate was higher in the Eda.B group (96.0% vs. 83.3%, p < 0.05), with similar adverse reaction rates (16.0% vs. 25.0%, p > 0.05). In conclusion, Eda.B showed superior effectiveness in improving neurological and cognitive function, cerebral perfusion, and reducing inflammation and oxidative stress in APCI patients.